search
Back to results

Compressive Device to Prevent Keloïd Scars Recurrence [SCARWARS] (SCARWARS)

Primary Purpose

Keloid

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Compression device
Sponsored by
Centre Hospitalier Universitaire de Besancon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Keloid focused on measuring ear lobe, compression, medical device, recurrence

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient over 18 yo;
  • Patient with aer lobe keloid;
  • Patient with an indication of reconstructive surgery;
  • Signature of informed consent from the patient;
  • Indication that the subject has understood the purpose and procedures required by the study and agrees to participate in the study and comply with the requirements and limitations inherent in this study;
  • Patient with French social insurance.

Exclusion Criteria:

  • Patient with cutaneous dermatosis or other skin pathology able to interfere with evaluated parameter (recurrence and healing quality);
  • Patient with know nickel allergy;
  • Patient with know silicon allergy;
  • Pregnant women;
  • Legal incapacity or limited legal capacity;
  • Patient unlikely to cooperate in the study and / or low cooperation anticipated by the investigator;
  • Patient without health insurance;
  • The patient is in the period of exclusion of another study.

Sites / Locations

  • CHU de BesançonRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Compression device

Arm Description

Outcomes

Primary Outcome Measures

Recurrence of keloid scar
Recurrence will be assessed during each visit by surgeon

Secondary Outcome Measures

Full Information

First Posted
October 12, 2017
Last Updated
July 29, 2021
Sponsor
Centre Hospitalier Universitaire de Besancon
search

1. Study Identification

Unique Protocol Identification Number
NCT03312166
Brief Title
Compressive Device to Prevent Keloïd Scars Recurrence [SCARWARS]
Acronym
SCARWARS
Official Title
First Study Evaluating Efficiency and Safety of a Compressive Device to Prevent Keloid Scars Recurrence After Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Unknown status
Study Start Date
October 3, 2017 (Actual)
Primary Completion Date
October 10, 2022 (Anticipated)
Study Completion Date
October 10, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Besancon

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
SCARWARS study deals with the first on-human evaluation of a compressive device dedicated to the prevention of keloïd scars recurrence after surgery. The tested device is made with clinical grade silicon. SCARWARS is a monocentric study. 27 patients will be include and follow during one year. The primary outcome of this study is the number of keloid recurrence after treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Keloid
Keywords
ear lobe, compression, medical device, recurrence

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
27 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Compression device
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Compression device
Intervention Description
interventions on patient are : surgical excision of ear lobe keloid application of compression device on sutured skin
Primary Outcome Measure Information:
Title
Recurrence of keloid scar
Description
Recurrence will be assessed during each visit by surgeon
Time Frame
12 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient over 18 yo; Patient with aer lobe keloid; Patient with an indication of reconstructive surgery; Signature of informed consent from the patient; Indication that the subject has understood the purpose and procedures required by the study and agrees to participate in the study and comply with the requirements and limitations inherent in this study; Patient with French social insurance. Exclusion Criteria: Patient with cutaneous dermatosis or other skin pathology able to interfere with evaluated parameter (recurrence and healing quality); Patient with know nickel allergy; Patient with know silicon allergy; Pregnant women; Legal incapacity or limited legal capacity; Patient unlikely to cooperate in the study and / or low cooperation anticipated by the investigator; Patient without health insurance; The patient is in the period of exclusion of another study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gwenael Rolin, PhD
Phone
0033 3 81 21 91 64
Email
grolin@chu-besancon.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Lihoreau Thomas, Ing
Email
tlihoreau@chu-besancon.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brice Chatelain, MD
Organizational Affiliation
Centre Hospitalier Universitaire de Besançon
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Besançon
City
Besançon
ZIP/Postal Code
25000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Lihoreau, Ing
Email
tlihoreau@chu-besancon.fr
First Name & Middle Initial & Last Name & Degree
Gwenaël Rolin, PhD
Email
grolin@chu-besancon.fr
First Name & Middle Initial & Last Name & Degree
Brice Chatelain, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Compressive Device to Prevent Keloïd Scars Recurrence [SCARWARS]

We'll reach out to this number within 24 hrs